Get the Daily Brief
Latest Biotech News
Automated MRI flags clinically significant prostate cancer: study in Nature Communications
A Nature Communications team introduced an automated MRI system designed to identify clinically significant prostate cancer reliably. The AI pipeline automates image analysis to reduce variability...
mRNA protects muscle from snake venom: COVID platform repurposed
Researchers from the University of Reading and the Technical University of Denmark demonstrated that mRNA encapsulated in lipid nanoparticles can induce protective antibodies in muscle and reduce...
Carolyn Bertozzi returns to Eli Lilly: Nobel chemist named to board Dec. 8
Eli Lilly disclosed in an SEC filing that Nobel laureate Carolyn Bertozzi will rejoin its board on Dec. 8. Bertozzi, who won the 2022 Nobel Prize in Chemistry for bioorthogonal chemistry, brings...
Avadel takeover tussle... Alkermes and Lundbeck spar in bidding duel
Avadel Pharmaceuticals became the focal point of a cross-border bidding contest after Alkermes agreed to acquire the company for up to ~$2.1 billion and Lundbeck surfaced with a rival proposal....
Blood biomarkers map Alzheimer’s progression: accessible tracking across cognitive stages
Researchers published a large community-based study in Nature Communications demonstrating blood biomarkers correlate with cognitive stage and can track Alzheimer’s disease progression outside...
Automated MRI for prostate cancer: AI system flags clinically significant tumors
A Nature Communications paper reports an automated MRI system that reliably detects clinically significant prostate cancer, reducing dependence on specialist radiologists. The model integrates MRI...
ASAH1 drives venetoclax resistance in AML: sphingolipid metabolism implicated
A BMC Cancer study identified ASAH1 and its impact on sphingolipid metabolism as a key mediator of resistance to venetoclax in acute myeloid leukemia, especially in monocytic phenotypes. The...
NSUN7–m5C axis sustains glioblastoma stemness: RNA modification as therapeutic target
New research reveals NSUN7-mediated m5C modification of circNTRK2 sustains glioblastoma stem cell properties, supporting tumor maintenance and therapy resistance. The study shows NSUN7 alters RNA...
Simple outpatient risk score predicts gastric cancer: externally validated PRS
Researchers developed and externally validated a prediction risk score (PRS) for gastric cancer designed for outpatient settings. The model uses readily available clinical and demographic...
Tumor exosomes drive brain metastasis: miR‑221‑3p promotes breast cancer colonization of brain
A Journal of Translational Medicine study showed tumor-derived exosomal miR-221-3p enhances breast cancer metastasis to the brain by reprogramming the brain microenvironment and supporting tumor...
MEF2C reverses cisplatin resistance in ovarian cancer: apoptosis reactivated
A new investigation found that activating the transcription factor MEF2C triggers intrinsic apoptosis and reverses cisplatin resistance in ovarian cancer cells. The authors demonstrated...
Talazoparib benefits BRCA‑mutant metastatic disease: multicenter retrospective evidence
A multicenter retrospective study reported durable responses to talazoparib in patients with BRCA-mutant metastatic breast and ovarian cancers, reinforcing the PARP inhibitor’s activity beyond...
Eli Lilly hits $1 trillion — pharma milestone
Eli Lilly reached a $1 trillion market valuation, marking the first time a pharmaceutical company has crossed that threshold. The milestone reflects outsized investor enthusiasm for the company’s...
Avadel takeover battle... Alkermes and Lundbeck duel
Avadel Pharmaceuticals is the focus of an active bidding contest after agreeing to an acquisition by Alkermes; Copenhagen-based Lundbeck countered with a higher proposal. Avadel’s board declared...
Medicaid coverage for GLP‑1s varies widely — study
A cross‑sectional analysis found substantial variation across state Medicaid programs in coverage and prior‑authorization requirements for antiobesity GLP‑1 receptor agonists. The paper by...
Semaglutide slows kidney disease progression — trial data
A clinical study reported that semaglutide, a GLP‑1 receptor agonist, reduces progression of kidney disease in patients with type 2 diabetes and chronic kidney disease. Researchers Alemu,...
Tirzepatide maintains weight-loss and diabetes prevention at three years
Longitudinal data show tirzepatide preserves weight‑loss efficacy and reduces diabetes incidence over a three‑year follow‑up, according to a study in the Journal of General Internal Medicine. The...
CombiCoR‑Vax trial launches: immunotherapy plus chemo for refractory MSS mCRC
Investigators opened the CombiCoR‑Vax phase II trial testing a sequential combination of immunotherapy and chemotherapy in refractory microsatellite‑stable metastatic colorectal cancer (mCRC). The...
Prophylactic third‑party NK cells after HSCT: safety signals in AML
A BMC Cancer study evaluated prophylactic infusions of third‑party natural killer (NK) cells following hematopoietic stem cell transplantation (HSCT) for high‑risk acute myeloid leukemia....
Distinct CD4 memory T‑cell program linked to type 1 diabetes — Science Immunology
Researchers from the University of Pennsylvania and the HPAP Consortium identified a conserved transcriptional and epigenetic program in a subset of CD4 memory helper T cells associated with type...